| アブストラクト | COVID-19 vaccination is critical in frequently immunocompromised patients with rheumatoid arthritis (RA). However, there is a question about the risk of RA flares following vaccination. Our study intended to find out about cases of new RA or flare-ups in people who already had RA that were reported in French and international pharmacovigilance databases after COVID-19 vaccination. We performed a "case-noncase" method in the international pharmacovigilance database VigiBase to identify the risk of RA following COVID-19 vaccination compared with other nonlive vaccines. Using the French Pharmacovigilance Database (FPVD), a descriptive analysis was carried out for RA cases after COVID-19 immunization and a multivariate logistic regression analysis was conducted to compare variables in the new-onset vs. flare-up groups. In 2021, 2,387 cases of RA were reported from 2,817,902 adverse drug reactions associated with COVID-19 vaccines recorded in VigiBase. The reporting odds ratio of RA onset with COVID-19 vaccines compared with the other nonlive vaccines was 0.66 (P < 0.0001). The FPVD reported 161 cases of RA with COVID-19 vaccines, including 77 new-onset RA and 84 cases of RA flare-up. In 88 cases (84.7%), RA occurred after the first dose. The mean time between vaccination and disease onset was 14 +/- 21 days, and the delay was significantly shorter in the flare-up group. We do not show a higher risk of RA after COVID-19 vaccination compared with other nonlive vaccines in adults. De novo RA was more likely to happen quickly, be more severe, and have a worse outcome than flares in patients with RA. |
|---|
| ジャーナル名 | Clinical pharmacology and therapeutics |
|---|
| Pubmed追加日 | 2023/2/9 |
|---|
| 投稿者 | Prontskus, Viktoryia; Fresse, Audrey; Yelehe-Okouma, Melissa; Facile, Anthony; Pietri, Tessa; Simon, Corinne; Le Souder, Cosette; Beurrier, Mathilde; Gillet, Pierre |
|---|
| 組織名 | Laboratoire de Pharmacologie-Toxicologie, Pharmacovigilance & Centre d'evaluation;et d'information sur la Pharmacodependance-Addictovigilance, Centre Hospitalier;Regional et Universitaire de Nancy Brabois, Batiment de Biologie Medicale et de;Biopathologie, Vandoeuvre-Les-Nancy, France.;Service Hospitalo-Universitaire de Pharmacotoxicologie, Hospices Civils de Lyon,;Lyon, France.;Centre Regional de Pharmacovigilance Marseille Provence Corse, Service de;Pharmacologie Clinique & Pharmacovigilance, Assistance Publique Hopitaux de;Marseille, Aix-Marseille Universite Institut National de la Sante et de la;Recherche Medicale 1106, Marseille, France.;Centre Regional de Pharmacovigilance, Service de Pharmacosurveillance, Centre;Hospitalier Regional et Universitaire, Tours, France.;Departement de Pharmacologie Medicale et Toxicologie, Centre Regional de;Pharmacovigilance Occitanie-Est, Le Centre Hospitalier et Universitaire de;Montpellier, Montpellier, France.;Universite de Lorraine, Centre National de la Recherche Scientifique, Ingenierie;Moleculaire et Physiopathologie Articulaire, Nancy, France. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/36752604/ |
|---|
